In the HER2+ breast cancer subtype, preclinical evidence has shown that inhibitors of the PI3K/AKT/mTOR pathway can enhance the antiproliferative activity of anti-HER2 therapies and/or overcome the acquired resistance to these agents (9, 27–33). This evidence concerns the gene MTOR and breast cancer.